Morgan Stanley Maintains Underweight on XPLR Infr, Lowers Price Target to $10

Benzinga · 3d ago
Morgan Stanley analyst Robert Kad maintains XPLR Infr (NYSE:XIFR) with a Underweight and lowers the price target from $11 to $10.